Pfizer, BioNTech start combined trials of Covid-19 vaccine candidate in Japan

Reuters Tokyo | Updated on October 20, 2020

Pfizer Inc and BioNTech SE announced on Tuesday the start in Japan of combined Phase I and Phase II clinical trials of their mRNA vaccine candidate against the coronavirus.

The study will recruit 160 people aged 20 to 85, the companies said in a statement. They had earlier agreed to supply Japan with 120 million doses of their experimental coronavirus vaccine in the first half of 2021.

Published on October 20, 2020

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like